Federal contractor · WEST CHESTER, PA

MOLECULAR TARGETING TECHNOLOGIES, INC.

No contract obligations recorded for MOLECULAR TARGETING TECHNOLOGIES, INC. in FY2026. Since FY2017: $350K. It also received $637.5K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
Y2FNW7N1V267
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 300KFY2017
  2. 50KFY2018

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for MOLECULAR TARGETING TECHNOLOGIES, INC. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

MOLECULAR TARGETING TECHNOLOGIES, INC. received $637.5K in federal assistance in FY2026, on 2 actions (1 new awards). Its largest program was 93.394 · Cancer Detection and Diagnosis Research ($637.5K).

Assistance · FY2026
$637.5K
New awards
1
Actions
2
Since FY2021
$3.9M

Assistance by fiscal year

  1. 514.4KFY2021
  2. 1.5MFY2022
  3. 1.3MFY2023
  4. 0FY2024
  5. -86.2KFY2025
  6. 637.5KFY2026

By type

  1. Grants$637.5K100%

Top programs

  1. 93.394 · Cancer Detection and Diagnosis Research$637.5K100%

Awarding agencies

  1. National Institutes of Health$637.5K100%
    Department of Health and Human Services

Largest awards

  1. INSTANTANEOUS TUMOR SPRAY FOR REAL-TIME SURGICAL GUIDANCE - EARLY STAGE OVARIAN CANCER IS TYPICALLY ASYMPTOMATIC. UNDIAGNOSED UNTIL THE…$2M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Aug 10, 2022 – Dec 18, 2025· R44CA275434
  2. TARGETED RADIONUCLIDE THERAPY FOR NON-SMALL CELL LUNG CANCER WITH LU-177 EBRGD - PROJECT SUMMARY/ABSTRACT: LUNG CANCER IS THE LEADING CAUSE…$637.5K
    93.394 · Cancer Detection and Diagnosis Research· National Institutes of Health· Project grant· Aug 24, 2026 – Aug 24, 2026· R01CA299133

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026.